174 related articles for article (PubMed ID: 1691406)
41. Effects of quinapril, a new angiotensin converting enzyme inhibitor, on left ventricular failure and survival in the cardiomyopathic hamster. Hemodynamic, morphological, and biochemical correlates.
Haleen SJ; Weishaar RE; Overhiser RW; Bousley RF; Keiser JA; Rapundalo SR; Taylor DG
Circ Res; 1991 May; 68(5):1302-12. PubMed ID: 1850330
[TBL] [Abstract][Full Text] [Related]
42. The efficacy and safety of quinapril in the treatment of moderate to severe and severe hypertension: comparison to captopril.
Frishman WH
Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII26-31. PubMed ID: 2189618
[TBL] [Abstract][Full Text] [Related]
43. Effects of the converting enzyme inhibitor quinapril (CI-906) on blood pressure, renin-angiotensin system, and prostanoids in essential hypertension.
Säynävälammi P; Pörsti I; Pörsti P; Nurmi AK; Seppälä E; Manninen V; Vapaatalo H
J Cardiovasc Pharmacol; 1988 Jul; 12(1):88-93. PubMed ID: 2459540
[TBL] [Abstract][Full Text] [Related]
44. Lymphocyte beta adrenoceptor upregulation and improved cardiac response to adrenergic stimulation following converting enzyme inhibition in congestive heart failure.
Townend JN; Virk SJ; Qiang FX; Lawson N; Bain RJ; Davies MK
Eur Heart J; 1993 Feb; 14(2):243-50. PubMed ID: 8383598
[TBL] [Abstract][Full Text] [Related]
45. The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.
Texter M; Lees RS; Pitt B; Dinsmore RE; Uprichard AC
Cardiovasc Drugs Ther; 1993 Apr; 7(2):273-82. PubMed ID: 8357782
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension.
Schnaper HW
Angiology; 1989 Apr; 40(4 Pt 2):389-95. PubMed ID: 2650582
[TBL] [Abstract][Full Text] [Related]
47. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
Larochelle P; Haynes B; Maron N; Dugas S
Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
[TBL] [Abstract][Full Text] [Related]
48. The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.
MacFadyen RJ; Bainbridge AD; Lees KR; Reid JL
Br J Clin Pharmacol; 1991 Sep; 32(3):393-8. PubMed ID: 1777377
[TBL] [Abstract][Full Text] [Related]
49. Speed and duration of dose titration with the angiotensin converting enzyme inhibitor quinapril: relationship with efficacy in patients with moderate hypertension.
Weir MR
J Hum Hypertens; 1994 Sep; 8(9):725-30. PubMed ID: 7807504
[TBL] [Abstract][Full Text] [Related]
50. Assessing the clinical need for short-term conversion from oral to parenteral angiotensin converting enzyme inhibitor therapy in hypertensive patients. A quinapril to quinaprilat placebo-controlled model.
Whelton A; McCormick L; Wombolt D; Goldstein R; Canter D
Eur Heart J; 1997 Jan; 18(1):140-7. PubMed ID: 9049526
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of heart failure in dogs with ACe inhibitors: comparison of quinapril and captopril].
Morisse B; Kersten U
Tierarztl Prax; 1995 Oct; 23(5):489-96. PubMed ID: 8585063
[TBL] [Abstract][Full Text] [Related]
52. An open, parallel group comparison of quinapril and captopril, when added to diuretic therapy, in the treatment of elderly patients with heart failure.
Beynon JH; Pathy MS
Curr Med Res Opin; 1997; 13(10):583-92. PubMed ID: 9327193
[TBL] [Abstract][Full Text] [Related]
53. Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Multicenter Study Group.
Larochelle P
Am J Hypertens; 1996 Jun; 9(6):551-9. PubMed ID: 8783779
[TBL] [Abstract][Full Text] [Related]
54. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
[TBL] [Abstract][Full Text] [Related]
55. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy.
Kontopoulos AG; Athyros VG; Didangelos TP; Papageorgiou AA; Avramidis MJ; Mayroudi MC; Karamitsos DT
Diabetes Care; 1997 Mar; 20(3):355-61. PubMed ID: 9051387
[TBL] [Abstract][Full Text] [Related]
56. Use of quinapril in the elderly patient.
Schnaper HW
Am J Hypertens; 1990 Nov; 3(11):278S-282S. PubMed ID: 2261146
[TBL] [Abstract][Full Text] [Related]
57. [Conversion from oral ACE inhibitor to intravenous quinaprilat administration in mild to moderate essential hypertension].
Schmidt BM; Smilde J; Oldenbroek C; Wehling M
Med Klin (Munich); 1998 Dec; 93(12):701-6. PubMed ID: 10024837
[TBL] [Abstract][Full Text] [Related]
58. Quinapril therapy in patients with chronic mitral regurgitation.
Schön HR; Schröter G; Barthel P; Schömig A
J Heart Valve Dis; 1994 May; 3(3):303-12. PubMed ID: 8087269
[TBL] [Abstract][Full Text] [Related]
59. Initiating angiotensin converting enzyme inhibitors in mild to moderate heart failure in general practice: randomised, placebo controlled trial.
Lough M; Cleland J; Langan J; Cowley A; Wade A
BMJ; 1998 Nov; 317(7169):1352-3. PubMed ID: 9812933
[No Abstract] [Full Text] [Related]
60. Efficacy and safety of quinapril in the elderly hypertensive patient.
Forette B; Koen R; Vicaut E
Am Heart J; 1992 May; 123(5):1426-32. PubMed ID: 1575170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
